Boston Biotech Faces Challenges as Founders Relocate to California

The approval follows a protracted regulatory process for the company’s drug development pipeline. This development coincides with broader shifts in the biotechnology sector, including a trend of founders leaving Boston for California and new research into the tau protein’s role in Alzheimer’s disease.

Replimune Secures FDA Approval

The U.S. Food and Drug Administration has granted approval to Replimune, ending a period of regulatory uncertainty for the company. STAT describes the approval as hard-fought, indicating the company faced significant hurdles during the review process before securing the authorization.

Alzheimer’s Research and Tau Protein Function

Medical researchers are reporting new findings regarding the function of tau proteins in the progression of Alzheimer’s disease.

Recent discoveries detailed by STAT suggest that researchers are uncovering more specific secrets of how tau functions.

Biotech Migration from Boston to California

Boston’s status as a global biotechnology hub is facing pressure as founders relocate their operations to California.

According to STAT, this trend puts the city’s identity as the biotech capital of the world under scrutiny.